Page last updated: 2024-12-08
acylfulvene
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
acylfulvene: an antineoplastic agent; structure given in first source; an analog of illudin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 365701 |
| CHEMBL ID | 121987 |
| SCHEMBL ID | 17168188 |
| MeSH ID | M0212601 |
Synonyms (19)
| Synonym |
|---|
| acylfulvene |
| NSC633555 , |
| nsc-633555 |
| NCI60_011189 |
| (-)-acylfulvene |
| CHEMBL121987 |
| bdbm50410833 |
| 125392-76-9 |
| SCHEMBL17168188 |
| DTXSID30327131 |
| Q4678004 |
| spiro[cyclopropane-1,5'-[5h]inden]-7'(6'h)-one, 6'-hydroxy-2',4',6'-trimethyl-, (6'r)- |
| acylfulvene, (-)- |
| (6'r)-6'-hydroxy-2',4',6'-trimethylspiro(cyclopropane-1,5'-(5h)inden)-7'(6'h)-one |
| illudofulvene |
| unii-g4t2fa57q6 |
| g4t2fa57q6 , |
| spiro(cyclopropane-1,5'-(5h)inden)-7'(6'h)-one, 6'-hydroxy-2',4',6'-trimethyl-, (r)- |
| (6'r)-6'-hydroxy-2',4',6'-trimethyl-6',7'-dihydrospiro(cyclopropane-1,5'-indene)-7'-one |
Research Excerpts
Overview
Acylfulvenes (AFs) are a class of antitumor agents derived from illudin S, a sesquiterpenoid toxin isolated from mushrooms of the genus Omphalotus. Clinical trials are ongoing for (-)-(hydroxymethyl)AF.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Acylfulvenes are a class of antitumor agents derived from illudin S, a sesquiterpenoid toxin isolated from mushrooms of the genus Omphalotus. " | ( Sulfotransferase-independent genotoxicity of illudin S and its acylfulvene derivatives in bacterial and mammalian cells. Glatt, H; Meinl, W; Pietsch, KE; Sturla, SJ, 2014) | 2.08 |
| "Acylfulvenes (AFs) are a class of antitumor agents with favorable cytotoxic selectivity profiles compared to their natural product precursor, illudin S. " | ( Profiling patterns of glutathione reductase inhibition by the natural product illudin S and its acylfulvene analogues. Liu, X; Sturla, SJ, 2009) | 2.01 |
| "Acylfulvenes (AFs) are a class of semisynthetic agents with high toxicity toward certain tumor cells, and for one analogue, hydroxymethylacylfulvene (HMAF), clinical trials are in progress. " | ( Depurinating acylfulvene-DNA adducts: characterizing cellular chemical reactions of a selective antitumor agent. Gong, J; Kensler, TW; Peterson, LA; Sturla, SJ; Vaidyanathan, VG; Yu, X, 2007) | 2.15 |
| "Acylfulvenes (AFs) are a class of antitumor agents that exert their cytotoxic effects by forming covalent adducts with biomolecules, including DNA and proteins; clinical trials are ongoing for (-)-(hydroxymethyl)AF. " | ( Quantitative correlation of drug bioactivation and deoxyadenosine alkylation by acylfulvene. Gong, J; Neels, JF; Sturla, SJ; Yu, X, 2007) | 2.01 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " In vitro killing of tumor cells by acylfulvene required up to a 30-fold increase in molecules per cell, as compared with illudin S, indicating that acylfulvene was less toxic on a cellular level." | ( Characterization of acylfulvene histiospecific toxicity in human tumor cell lines. Bagnell, RD; Estes, L; Kelner, MJ; McMorris, TC; Montoya, MA; Rutherford, M; Samson, KM; Taetle, R; Uglik, SF, 1998) | 0.9 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Prostaglandin reductase 1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0950 | 0.0550 | 0.0750 | 0.0950 | AID262580 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Other Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID262581 | Affinity towards rat NADP-dependent AOR, leukotriene B4 12-hydroxydehydrogenase | 2006 | Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8 | Investigating the role of stereochemistry in the activity of anticancer acylfulvenes: synthesis, reductase-mediated bioactivation, and cellular toxicity. |
| AID355132 | Cytotoxicity against human HL60 cells after 48 hrs by trypan blue exclusion method | 1996 | Journal of natural products, Sep, Volume: 59, Issue:9 | (Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties. |
| AID262579 | Cytotoxicity against HEK293 cells by MTT assay | 2006 | Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8 | Investigating the role of stereochemistry in the activity of anticancer acylfulvenes: synthesis, reductase-mediated bioactivation, and cellular toxicity. |
| AID262580 | Cytotoxicity against HEK293 cells transfected with recombinant AOR by MTT assay | 2006 | Journal of medicinal chemistry, Apr-20, Volume: 49, Issue:8 | Investigating the role of stereochemistry in the activity of anticancer acylfulvenes: synthesis, reductase-mediated bioactivation, and cellular toxicity. |
| AID7788 | Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells. | 2000 | Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19 | Preparation and biological activity of amino acid and peptide conjugates of antitumor hydroxymethylacylfulvene. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (22)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (22.73) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 9 (40.91) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 22.03
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.03) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 20 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||